Phase 3 Pancreatic Cancer Trial, Recruiting NCT07436741 Sponsor: Tianjin Medical University Cancer Institute and Hospital Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Phase 3 Pancreatic Cancer Trial, Recruiting

NCT07436741
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with high-risk or borderline resectable pancreatic cancer, confirmed through a tissue or cell sample test
  • People aged 18 to 75 years old (inclusive)
  • People who do not carry mutations in the BRCA1, BRCA2, or PALB2 genes
  • People who have not previously had surgery, drug treatment, or radiation therapy for pancreatic cancer
  • People with a good general level of physical functioning, rated 0 or 1 on a standard oncology scale (ECOG scale)
  • People with a life expectancy of at least 6 months
  • People who have at least one tumour that can be measured using standard imaging criteria (RECIST v1.1)
  • People whose organs and bone marrow are functioning at adequate levels
  • Women who are able to become pregnant and are willing to use effective contraception during the trial

Who may not be able to join:

  • People whose cancer has spread to distant parts of the body
  • People who have received a blood transfusion, blood products, or blood-boosting medications (such as albumin or G-CSF) within the 14 days before joining
  • People who have had surgery or another invasive procedure within 4 weeks before joining (minor procedures such as a venous catheter, needle biopsy, or drainage may be exceptions — confirm with trial site)
  • People with a known allergy to the study drug or any of its ingredients
  • People with electrolyte (blood mineral) abnormalities considered clinically significant by the trial doctors
  • People with a history of serious heart or stroke-related conditions
  • People with an active stomach or intestinal ulcer, a hole in the intestine, or a bowel blockage
  • People with uncontrolled fluid build-up in the abdomen (ascites) that cannot be managed with water tablets or drainage
  • People with active bleeding or a clear tendency to bleed
  • People with high blood pressure that cannot be controlled with medication (systolic at or above 150 mmHg and/or diastolic at or above 100 mmHg)
  • Women who are pregnant or breastfeeding
  • People with significant amounts of protein detected in their urine (at or above a certain threshold on testing)
  • People who have had another cancer diagnosis within the past 5 years, with the exception of certain treated early-stage cancers such as cervical carcinoma in situ or basal cell skin cancer
  • People who have difficulty swallowing or absorbing oral medications, or who are unable to take medications by mouth
  • People with a known HIV infection
  • People with significant liver disease, including active hepatitis B or C infection with detectable virus levels, or cirrhosis
  • People who have any other medical condition, abnormal test result, or other circumstance that the trial doctors consider would make participation unsuitable

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Jihui Hao, M.D., Tianjin Medical University Cancer Institute and Hospital

Phone: 022-23524155

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Registry
ClinicalTrials.gov
Start date
3 March 2026
Est. completion
1 September 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Surgical complete resection rate (R0)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov